Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13252103 | 0.84 | BRAF (0.46) | BRAFMAP4K1PTK2FLT3IGF1R | |
| SCHEMBL13574109 | 0.81 | BRAF (0.48) | BRAFRAF1 | |
| SCHEMBL13225903 | 0.80 | BRAF (0.41) | BRAFMAP4K1PTK2FLT3IGF1R | |
| SCHEMBL13252021 | 0.78 | CDK4 (0.42) | BRAFWEE1 | |
| SCHEMBL31460972 | 0.70 | F9 (0.46) | BRAFPTK2FLT3IGF1R | |
| SCHEMBL12671181 | 0.69 | ALK (0.42) | BRAFPTK2FLT3WEE1MAP3K5 | |
| SCHEMBL17529301 | 0.69 | BRAF (0.49) | BRAFMAP4K1PTK2 | |
| SCHEMBL12120858 | 0.68 | BRAF (0.53) | BRAFIGF1RWEE1 | |
| SCHEMBL27834469 | 0.68 | CDK2 (0.49) | PTK2 | |
| SCHEMBL12123993 | 0.68 | BRAF (0.47) | BRAFIGF1RWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716478-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRAF 316/4885MAP4K1 49/4885PTK2 567/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | BRAF 208/4885MAP4K1 112/4885PTK2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.